Oppenheimer analyst Leland Gershell reiterated an Outperform rating on Crinetics (NASDAQ: CRNX).The analyst commented: "Palsonify's approval marks a major milestone ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE